Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Revenue (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Revenue for 9 consecutive years, with $438000.0 as the latest value for Q4 2025.

  • Quarterly Revenue changed N/A to $438000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $789000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $789000.0 for FY2025, N/A changed from the prior year.
  • Revenue hit $438000.0 in Q4 2025 for Seres Therapeutics, up from $351000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $126.7 million in Q3 2021 to a low of -$126.3 million in Q4 2023.
  • Historically, Revenue has averaged $10.9 million across 4 years, with a median of $1.4 million in 2022.
  • Biggest YoY gain for Revenue was 10300.74% in 2023; the steepest drop was 13049.85% in 2023.
  • Year by year, Revenue stood at $7.2 million in 2021, then tumbled by 86.5% to $975000.0 in 2022, then plummeted by 13049.85% to -$126.3 million in 2023, then surged by 100.35% to $438000.0 in 2025.
  • Business Quant data shows Revenue for MCRB at $438000.0 in Q4 2025, $351000.0 in Q3 2025, and -$126.3 million in Q4 2023.